<DOC>
	<DOC>NCT00473889</DOC>
	<brief_summary>This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin</brief_summary>
	<brief_title>A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Males and females at least 18 years of age who have confirmed diagnosis of Nonsmall Cell Lung Cancer Patients with no systemic prior systemic treatment for lung cancer except patients at least 12 months from prior adjuvant therapy Adequate bone marrow,kidney and liver function Must be recovered and at least 4 weeks from major surgery or radiation ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1 Men and women must agree to use birth control during the study Women able to have children must have a negative pregnancy test 14 days before study enrollment Patients with prior treatment with other investigational agents less than 4 weeks before study enrollment Pregnant or nursing female patients Patients who are HIV positive Patients who have Hepatitis A, B, or C Patients unable to take study medication by mouth Patients with untreated brain cancer Patient eligible for treatment with bevacizumab and for whom bevacizumab is available</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>